Project Grant R01DA062441
Award Date
8/1/25
Completion Date
4/30/30
Dollars Obligated
$825K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This federal Project Grant award of $476,123.00 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to leverage machine learning and genomic technologies to investigate how genetic variants associated with substance use disorders and sleep phenotypes may impact the circadian regulation of gene expression. The research will be conducted by Carnegie Mellon University and involves several key activities:...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $458,452 to the University of Utah to conduct research on the interrelationship between sleep, circadian rhythms, and substance use disorders. The key objectives are to: 1) determine the mechanisms of psychostimulant-induced sleep changes, 2) screen Drosophila orthologs of human brain-enriched transcripts for their role in...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
The National Institute on Drug Abuse (NIDA) awarded a $249,860 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to President and Fellows of Harvard College, doing business as Harvard Medical School, to conduct research on the relationship between REM sleep disruption, substance use disorders, and affective disorders. The research aims to delineate the function and brain circuitry involving a specialized subtype of dual serotonergic-glutamatergic neuron that could link sleep...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $465,669 to Virginia Commonwealth University (VCU) to conduct a mechanistic study on the role of the orexin system and insomnia within a buprenorphine opioid use disorder (OUD) treatment sample. The study aims to identify differences in drug cue-elicited brain connectivity between OUD patients with and without clinically significant...
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
This $585,975 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to discover and functionally characterize long non-coding RNAs (lncRNAs) in opioid use disorder (OUD) within the context of HIV at single-cell resolution. The University of Massachusetts Medical School will lead this 5-year effort to systematically identify novel lncRNAs in human and mouse brain tissues affected by OUD and HIV,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $454,251 to The Trustees of the University of Pennsylvania to develop a novel "released markers of activity" (RMAs) blood-based monitoring system for long-term tracking of neural circuit activity and opioid receptor gene expression changes in mice exposed to opioids. The goal is to better understand the molecular and functional...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop high-precision epigenetic therapeutics for treating opioid use disorder (OUD). The $398,137 award to Boston Interactome LLC, effective May 1, 2025 through April 30, 2026, will fund research to identify functional modulators of the G9A epigenetic protein complex that regulates DFosB expression under chronic opioid exposure. The goal...